📄 medicine

Quantitative Assessment of Regional Aerosol Deposition and Early Airway Clearance Using [18F]NaF Nebulized Inhalation PET/CT

This prospective study demonstrates that aerosolized [18F]NaF PET/CT effectively quantifies significantly reduced regional deposition and mucociliary-dominant early clearance in bronchiectatic lungs compared to healthy tissue, establishing 0 minutes as the optimal time point for assessing aerosol delivery.

Original authors: Xinlu Zhang, Ruiyue Zhao, Shaoyu Liu, Yu Wang, Ziqi Zhang, Shaonan Zhong, Xiang Yan, Zeguang Zheng, Nanshan Zhong, Linling Cheng, Xinlu Wang

Published 2026-06-28

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Xinlu Zhang, Ruiyue Zhao, Shaoyu Liu, Yu Wang, Ziqi Zhang, Shaonan Zhong, Xiang Yan, Zeguang Zheng, Nanshan Zhong, Linling Cheng, Xinlu Wang

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your lungs as a vast, intricate city of airways. In a healthy city, the roads are smooth, and delivery trucks (medicines) can drive straight to every neighborhood. But in a city with bronchiectasis, the roads are damaged, widened, and clogged with debris. The delivery trucks get stuck or crash before they ever reach the neighborhoods that need help most.

This study is like sending out a fleet of glowing delivery trucks to see exactly where they get stuck and how long they stay there.

Here is the simple breakdown of what the researchers did and found:

1. The "Glow-in-the-Dark" Test

The researchers wanted to see exactly where inhaled medicine lands in the lungs. Usually, doctors can only guess where the medicine goes based on how well a patient breathes or how they feel. But you can't actually see the medicine.

To fix this, they used a special "glowing" liquid called [18F]NaF. Think of this liquid as a high-tech, glowing paint.

They turned this paint into a mist (aerosol) using a nebulizer (a machine that turns liquid into a fine fog).
Patients breathed this glowing fog in for 5 minutes.
Then, they used a PET/CT scanner (a super-powerful camera that sees light) to take pictures of the lungs.

2. The "Broken City" Discovery

When they looked at the pictures, the results were very clear:

Healthy Areas: The "healthy" parts of the lungs lit up brightly. The glowing paint covered these areas well.
Damaged Areas (Bronchiectasis): The damaged parts of the lungs looked like dark holes or "ghost towns." The glowing paint barely reached them.

The Analogy: Imagine spraying perfume in a room. In a clean room, the scent fills the whole space. But if you spray it into a room filled with giant, sticky spiderwebs (the damaged airways), the scent gets trapped in the webs near the door and never reaches the back of the room. The study showed that in bronchiectasis, the medicine gets trapped in the wrong places and misses the sick areas entirely.

3. Does the "Spray Bottle" Matter?

The researchers tested three different types of spray machines (nebulizers): a jet-powered one, a mesh one, and an ultrasonic one.

The Result: It didn't matter which machine they used. The "dark holes" in the damaged lungs remained dark.
The Lesson: The problem isn't the machine; it's the shape of the lungs themselves. No matter how you spray the medicine, the damaged airways are too clogged or weirdly shaped to let it in.

4. Does Medicine Help the "Traffic"?

Some patients took a "bronchodilator" (a medicine that opens up airways, like relaxing a tight muscle) before the test. The researchers hoped this would open the roads and let the glowing paint flow better.

The Result: It didn't work. The roads stayed clogged, and the medicine still couldn't get through.
The Lesson: In bronchiectasis, the damage is structural (like a collapsed building), not just a temporary muscle spasm. Opening the muscles doesn't fix the broken roads.

5. How Fast Does the "Paint" Wash Away?

The researchers watched the glowing paint for up to 2 hours to see how the body cleared it.

The Main Mechanism: They found that the body clears the paint mostly by sweeping it away with tiny hairs (mucociliary transport), like a conveyor belt moving trash out of a factory.
The Surprise: Very little of the paint actually soaked into the bloodstream. It stayed in the airways and was swept away.
The Timing: The best time to see where the medicine landed was immediately after breathing it in. Waiting longer just showed the medicine being swept away, not where it originally landed.

The Bottom Line

This study proved that we can now use a glowing camera to see exactly where inhaled medicine fails to reach in patients with bronchiectasis.

The medicine consistently misses the damaged areas.
Changing the spray machine or using opening medicines doesn't fix this.
The body clears the medicine by sweeping it out, not by absorbing it into the blood.

This gives doctors a new, clear way to understand why inhaled treatments might not be working for these patients: the medicine simply can't get to the right place.

Technical Summary: Quantitative Assessment of Regional Aerosol Deposition and Early Airway Clearance Using [18F]NaF Nebulized Inhalation PET/CT

Problem Statement
Current management of chronic respiratory diseases relies heavily on inhalation therapy, yet the actual efficiency and regional distribution of aerosolized drugs within the complex airway architecture remain largely invisible. Standard clinical assessments (e.g., spirometry) provide indirect metrics that fail to map spatial deposition. Existing imaging modalities have significant limitations: High-Resolution CT (HRCT) visualizes structural abnormalities but cannot track aerosols; ventilation scintigraphy and hyperpolarized 129Xe MRI are often restricted to qualitative planar analysis or utilize gases/nanoparticles that follow airflow to alveoli, failing to replicate the inertial impaction behavior of therapeutic-sized aqueous droplets (>3 µm). Furthermore, previous Positron Emission Tomography (PET) studies have largely been limited to global lung measurements without region-specific quantification or systematic evaluation of clearance dynamics. There is a critical need for a method that can quantitatively visualize the true delivery patterns of therapeutic-sized aerosols and distinguish between mechanical airway clearance and systemic absorption.

Methodology
This prospective, observational methodological study developed and validated a standardized PET/CT framework using aerosolized [18F]sodium fluoride ([18F]NaF) to assess regional deposition and clearance in patients with bronchiectasis.

Study Population: 77 adults with CT-confirmed bronchiectasis were enrolled. The cohort was stratified by nebulizer type (jet, mesh, or ultrasonic) and, within the jet nebulizer group, by inhalation regimen (saline control vs. saline plus bronchodilator).
Radiopharmaceutical & Administration: [18F]NaF was prepared as a sterile saline solution (~370 MBq). It was nebulized to a mass median aerodynamic diameter (MMAD) of ~3 µm and inhaled via tidal breathing for 5 minutes. [18F]NaF was chosen as a surrogate tracer because, as a dissolved ionic tracer, it mimics the solvent phase of clinical medications and, crucially, has poor epithelial permeability, ensuring it remains trapped in the airway surface liquid without confounding systemic absorption.
Imaging Protocol: Participants underwent a static whole-lung PET/CT scan at 5 minutes post-inhalation (0-min scan) to assess deposition. A subset underwent dynamic PET imaging (0–30 min) followed by serial static scans up to 120 minutes to characterize clearance kinetics.
Image Analysis & Quantification:
- VOI Definition: Bronchiectatic regions (dilated, thickened walls) and healthy lung regions were manually delineated on co-registered PET/CT images.
- Metrics: Deposition was quantified using the Target-to-Blood Ratio (TBR) and total deposited activity (SUVmean × Volume).
- Kinetic Modeling: A dual-pathway clearance model was applied to dynamic data to partition the total clearance rate ( $k_{tot}$ ) into mucociliary transport ( $k_{mc}$ ) and systemic absorption ( $k_{abs}$ ). $k_{abs}$ was estimated using T10 vertebral bone accumulation as a proxy for blood-borne tracer.

Key Results

Regional Deposition Deficits: Qualitative and quantitative analysis at 0 minutes revealed significant deposition deficits in bronchiectatic regions compared to healthy lung. Bronchiectatic regions showed significantly lower TBR (median 1.30 vs. 2.30 in healthy lung; $p < 0.05$ ) and markedly reduced total activity (median 43.18 vs. 1413.33; $p < 0.0001$ ).
Robustness Across Conditions: The deposition deficit was consistent across all nebulizer types (jet, mesh, ultrasonic) and was not reversed by acute bronchodilator administration. This indicates the impairment is a consequence of the disease's structural and physiological barriers rather than device-specific artifacts or reversible bronchospasm.
Clearance Kinetics: Dynamic imaging showed that early clearance (0–30 min) was dominated by mucociliary transport ( $k_{mc} > k_{abs}$ ), with systemic absorption being negligible. Serial scans (up to 120 min) confirmed that activity in bronchiectatic regions did not increase over time, while healthy lung activity declined gradually, establishing 0 minutes as the optimal time point for deposition assessment.
Tracer Specificity: The study confirmed that [18F]NaF does not undergo significant cellular uptake or metabolic trapping, unlike [18F]FDG, ensuring that signal intensity correlates exclusively with deposited aerosol mass rather than pathological metabolic activity.

Significance and Claims
The paper claims to establish a robust, non-invasive imaging framework that directly visualizes the spatial fate of therapeutic-sized aerosols, addressing a gap left by traditional ventilation imaging. By utilizing [18F]NaF, the study successfully distinguishes between mechanical mucociliary clearance and systemic absorption, providing a physiologically specific surrogate for airway clearance dynamics.

The authors position this approach as a paradigm shift for evaluating inhaled drug efficiency, particularly in diseases with heterogeneous ventilation like bronchiectasis. The findings demonstrate that structurally abnormal airways are systematically disadvantaged in receiving aerosolized medications due to rigid remodeling and mucus plugging, a deficit that persists regardless of nebulizer type or bronchodilator use. The study suggests this quantitative framework can serve as a functional biomarker for stratifying disease phenotypes and acting as a pharmacodynamic endpoint in trials for mucoactive agents, inhaled antibiotics, and physiotherapy, with potential extension to other obstructive diseases like COPD and cystic fibrosis.